Methods: Pts with histologically proven BTC who progressed on at least one line of systemic
therapy received nivolumab 240mg IV q2weeks for 16 weeks and then 480 mg IV every 4 …

4097 Background: Biliary tract cancers (BTC) are often typically diagnosed at an advanced
stage. There is no established second line option for patients with advanced BTC who have …

4582 Background: Patients (pts) with advanced biliary tract cancers (BTC) have poor
prognosis with a median overall survival (OS) less than 12 months (mos). This randomized …

533 Background: Patients with advanced biliary tract cancer (BTC) have a poor prognosis,
and high unmet medical needs still exist for the treatment of this disease. Nivolumab has …

Importance Currently, there is no established second-line systemic treatment for biliary tract
cancer (BTC). Preclinical data have demonstrated that the presence of tumor-infiltrating CD8 …

e16216 Background: Patients with advanced unresectable BTC have a poor prognosis, and
treatment options are limited and with variable response rates. Nivolumab (NIVO), a PD-1 …

Background This study aimed to assess the safety and tolerability of the immune checkpoint
inhibitor nivolumab, as monotherapy or combined with chemotherapy, in Japanese patients …

338 Background: Our previous phase II study demonstrated that nivolumab provides modest
but durable clinical efficacy in patients (pts) with refractory biliary tract cancer (BTC) …

TPS541 Background: Patients (pts) with advanced biliary tract cancers (BTC) have poor
prognosis with a median overall survival (OS) less than 12 months. This randomized, multi …

Objective PD-1 inhibitors have improved efficacy in many cancers. There are currently no
reports of the use of PD-1 inhibitors, such as nivolumab, for metastatic biliary tract cancer …